Drug profile · INN
covid-19 (sars-cov-2) vaccine (recombinant adenovirus vector)
JCOVDEN
covid-19 (sars-cov-2) vaccine (recombinant adenovirus vector) (JCOVDEN) is an FDA-listed pharmaceutical active ingredient.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — covid-19 (sars-cov-2) vaccine (recombinant adenovirus vector)
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
covid-19 (sars-cov-2) vaccine (recombinant adenovirus vector) (JCOVDEN) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN covid-19 (sars-cov-2) vaccine (recombinant adenovirus vector)
Brand JCOVDEN
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Frequently asked questions
What is covid-19 (sars-cov-2) vaccine (recombinant adenovirus vector)?
covid-19 (sars-cov-2) vaccine (recombinant adenovirus vector) (JCOVDEN) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for covid-19 (sars-cov-2) vaccine (recombinant adenovirus vector)?
JCOVDEN is a marketed brand name for covid-19 (sars-cov-2) vaccine (recombinant adenovirus vector). Check FDA Drugs@FDA for the current US label holder and prescribing information.